Geode Capital Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Geode Capital Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,710	Closed	-$7K	–	5112
2022 Q2	$7K	Hold	1,710	–	–	﹤0.01%	4999
2022 Q1	$17K	Hold	1,710	–	–	﹤0.01%	4937
2021 Q4	$25K	Hold	1,710	–	–	﹤0.01%	4932
2021 Q3	$50K	Buy	1,710 +867	+103%	+$24.5K	﹤0.01%	4781
2021 Q2	$28K	Buy	843 +314	+59%	+$11.7K	﹤0.01%	4699
2021 Q1	$21K	Buy	+529	New	+$32.9K	﹤0.01%	4444
2020 Q4	–	Sell	-251	Closed	-$33K	–	4329
2020 Q3	$33K	Hold	251	–	–	﹤0.01%	4079
2020 Q2	$42K	Hold	251	–	–	﹤0.01%	4002
2020 Q1	$36K	Hold	251	–	–	﹤0.01%	3974
2019 Q4	$82K	Hold	251	–	–	﹤0.01%	4010
2019 Q3	$125K	Hold	251	–	–	﹤0.01%	3896
2019 Q2	$152K	Buy	251 +64	+34%	+$39.2K	﹤0.01%	3857
2019 Q1	$114K	Hold	187	–	–	﹤0.01%	3870
2018 Q4	$68K	Hold	187	–	–	﹤0.01%	3938
2018 Q3	$126K	Hold	187	–	–	﹤0.01%	3883
2018 Q2	$162K	Buy	187 +139	+290%	+$159K	﹤0.01%	3776
2018 Q1	$60K	Hold	48	–	–	﹤0.01%	3928
2017 Q4	$72K	Hold	48	–	–	﹤0.01%	3878
2017 Q3	$99K	Buy	+48	New	+$113K	﹤0.01%	3828
2017 Q2	–	Sell	-46	Closed	-$139K	–	4129
2017 Q1	$139K	Buy	+46	New	+$112K	﹤0.01%	3756

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management's NBRV Position: Q3 2022 in Review

Geode Capital Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2022, closing a stake of 1,710 shares — an estimated $7K sold.

Geode Capital Management first reported a position in NBRV in Q1 2017 and held it in 20 quarters. The position peaked at $162K in Q2 2018. 13 funds tracked by Wall St. Rank hold NBRV as of Q3 2022.

Geode Capital Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2022 after selling out during the quarter.
Geode Capital Management sold 1,710 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2022, an estimated $7K.
Geode Capital Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2017 and held it in 20 quarters.
Geode Capital Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $162K in Q2 2018.
13 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2022.

Based on Geode Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.